GO
Loading...

Pharmaceuticals

More

  • NEW YORK— Over-the-counter medicines maker Perrigo said Tuesday it is turning down a buyout offer from generic drugmaker Mylan that valued the company at $205 per share, or almost $29 billion, because it's too low. Perrigo said that Mylan's offer undervalues its business, including its product pipeline and its recent purchase of Belgium's Omega Pharma, one of...

  • Perrigo rejects $205/share bid from Mylan Tuesday, 21 Apr 2015 | 4:26 PM ET

    April 21- Dublin- based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company. Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros acquisition of Omega Pharma and new products that are expected to generate about $1...

  • Perrigo board unanimously rejects Mylan proposal Tuesday, 21 Apr 2015 | 4:04 PM ET
    Perrigo facility in Allegan, Michigan

    Perrigo announced Tuesday that its board of directors unanimously rejected the unsolicited bid from Mylan.

  • Similar to dietary supplements, the FDA does not review the safety or effectiveness of homeopathic remedies before they are sold. In perhaps the most serious case, in 2009 the FDA ordered the maker of Zicam to stop marketing three products that contained zinc gluconate. In 2010, the FDA warned about reports of toxicity in children taking Hyland Homeopathic's...

  • April 21- Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week, according to a source familiar with the matter. Teva said that its offer for Mylan is contingent on the company not completing an acquisition of Perrigo or any alternative transaction. Representatives from Perrigo and...

  • Time to take profits in biotech?   Tuesday, 21 Apr 2015 | 12:35 PM ET
    Time to take profits in biotech?

    CNBC's Meg Tirrell discusses major pharma deals ahead including Teva's proposal for rival Mylan.

  • MUMBAI, April 21- An Indian parliamentary committee has recommended that price caps should be extended to all drugs in the country and that the government should expedite the capping process. Indian law allows the National Pharmaceutical Pricing Authority regulator to fix prices of drugs on a list of essential medicines, thereby keeping prices in check in a...

  • *Dow components Verizon, DuPont and United Tech beat estimates. *Yahoo, Chipotle, Yum to report after markets close. Mylan rose as much as 9.4 percent to a record high of $74.44 after Israeli drugmaker Teva made an unsolicited offer of $82 per share, in what could be the drug industry's largest takeover this year.

  • TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. on Tuesday proposed buying smaller rival Mylan for $40 billion, saying it was a better deal than Mylan's alternate offer to buy Perrigo Co. Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10, which it said was the...

  • Teva offers to buy Mylan in $40.1B cash-and-stock deal Tuesday, 21 Apr 2015 | 9:14 AM ET

    TRENTON, N.J.— Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators. If Israel- based Teva Pharmaceutical Industries Ltd. succeeded, the combination would...

  • UPDATE 1-Teva makes $82 per share offer for Mylan Tuesday, 21 Apr 2015 | 8:57 AM ET

    TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and cash.

  • *Global nutraceutical market seen at $280 bln by 2018. LONDON, April 21- A boom in "nutraceuticals"- food and drinks with potential health benefits- is paving the way for a rush of deals, as food and drug companies compete to dominate a market expected to be worth $280 billion by 2018.. "The space is ripe for M&A and I think you are going to see more," added Jeremy Johnson,...

  • Asian stocks mostly higher as Japan exports improve Tuesday, 21 Apr 2015 | 12:31 AM ET

    TAKING IT ALL IN: "It seems the market is in a holding pattern as investors are waiting to see just how much the dollar impacts corporate earnings," said Russell Price, Ameriprise Financial's senior economist. The chemical giant also lowered its forecast for full-year profits, and its stock fell $2.15, or 3 percent, to $70.70. CLEANING UP: Kimberly-Clark jumped 4...

  • Big biotech movers: Juno & Kite   Monday, 20 Apr 2015 | 2:42 PM ET
    Big biotech movers: Juno & Kite

    Shares of Juno Therapeutics and Kite Pharmaceuticals are falling today based on news coming out of a big cancer conference over the weekend, reports CNBC's Meg Tirrell.

  • NEW YORK— Israeli drugmaker Teva Pharmaceutical Industries said Monday that it will pay $512 million to resolve lawsuits accusing its Cephalon division of making illegal payments that kept cheaper generic versions of its sleep disorder drug Provigil off the market, boosting Cephalon's sales. The company set aside $495 million in 2013 to cover potential...

  • Promising cancer drugs   Friday, 17 Apr 2015 | 4:42 PM ET
    Promising cancer drugs

    The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.

  • Shares of Mylan NV rose $2.98, or 4.5 percent, to $69.82. Earlier this month Mylan offered to buy generic drug and ingredients maker Perrigo for about $29 billion, or $205 per share. Perrigo, which is based in Ireland, said it would review Mylan's offer.

  • Mylan: Fully committed to stand alone strategy   Friday, 17 Apr 2015 | 2:50 PM ET
    Mylan: Fully committed to stand alone strategy

    CNBC's Dominic Chu reports the latest on Mylan and their pending acquisition of Perrigo.

  • Teva considering potential bid for Mylan - Bloomberg Friday, 17 Apr 2015 | 2:37 PM ET

    April 17- Teva Pharmaceuticals Industries is considering a bid for Mylan NV, Bloomberg reported, citing people familiar with the matter. Teva has not made a formal approach, Bloomberg reported. Generic drugmaker Mylan offered to buy Perrigo Co Plc for about $29 billion in cash and stock in early April.

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...